These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 36921334)

  • 1. Flashback Foreword: Activity of First-Line Trastuzumab.
    Griggs JJ
    J Clin Oncol; 2023 Mar; 41(9):1635-1636. PubMed ID: 36921334
    [No Abstract]   [Full Text] [Related]  

  • 2. Deciphering trastuzumab resistance in residual tumor according to HER2 status after neoadjuvant trastuzumab containing regimen in HER2 positive breast cancer patients might help to choose further adjuvant anti-HER2 treatment.
    Abduyev Z; Altundag K
    J BUON; 2019; 24(5):2208. PubMed ID: 31786900
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of trastuzumab and lapatinib on HER2 positive breast cancer treatment.
    Jia W; Wang TZ
    J Biol Regul Homeost Agents; 2019 Mar-Apr,; 33(2):551-555. PubMed ID: 30907562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trastuzumab beyond progression in HER2-positive metastatic breast cancer.
    Al-Naqqash M; Jasim Al-Serarati W; Farooq Kareem T
    Breast J; 2021 Mar; 27(3):297-299. PubMed ID: 33472271
    [No Abstract]   [Full Text] [Related]  

  • 5. Enlisting the Immune System to Cure Breast Cancer--A Recipe for Success.
    Adams S
    JAMA Oncol; 2016 Jan; 2(1):25-7. PubMed ID: 26468637
    [No Abstract]   [Full Text] [Related]  

  • 6. Misconception on the duration of ado-trastuzumab emtansine treatment for HER2-positive early breast cancer.
    Chung C
    Am J Health Syst Pharm; 2022 May; 79(10):717-718. PubMed ID: 35021198
    [No Abstract]   [Full Text] [Related]  

  • 7. A systematic review of the economic evaluations of trastuzumab in metastatic breast cancer.
    Petrou P
    Breast J; 2020 Sep; 26(9):1903-1905. PubMed ID: 32383220
    [No Abstract]   [Full Text] [Related]  

  • 8. Improved progression-free survival in metastatic breast cancer.
    Burki TK
    Lancet Oncol; 2018 Feb; 19(2):e79. PubMed ID: 29276020
    [No Abstract]   [Full Text] [Related]  

  • 9. Lapatinib plus capecitabine in metastatic human epidermal growth factor receptor 2-positive breast cancer patients that received prior therapy with trastuzumab and pertuzumab: Better option than T-DM1?
    Altundag K
    J BUON; 2017; 22(1):281-282. PubMed ID: 28365969
    [No Abstract]   [Full Text] [Related]  

  • 10. When to Add Additional Anti-HER2 Therapy to Adjuvant Trastuzumab.
    Zimmer AS; Denduluri N
    Curr Oncol Rep; 2019 Nov; 21(12):109. PubMed ID: 31781874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States.
    Danese MD; Masaquel A; Santos E; Brammer M; Lee A; Lalla D
    Value Health; 2015 Sep; 18(6):876-83. PubMed ID: 26409616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
    Farhat F; Kattan JG; Ghosn M
    Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. De-escalation of breast cancer treatment for Her2-positive breast cancer.
    Swarnkar P; Mokbel L; Mokbel K
    Breast Cancer Res Treat; 2022 Nov; 196(1):243-244. PubMed ID: 36083382
    [No Abstract]   [Full Text] [Related]  

  • 14. Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer.
    Yu YF; Wang Y; Fu TP; Chen K; Liu JQ; Yao HR
    Breast Cancer Res Treat; 2018 Apr; 168(2):337-348. PubMed ID: 29188398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Dual Role of Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Two Sides of the Same Coin?
    Loibl S
    JAMA Oncol; 2015 Jul; 1(4):455-6. PubMed ID: 26181253
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer.
    Claessens AKM; Busschbach JJV; Ramaekers BLT; Erdkamp FLG; Bouma JM; van Leeuwen-Stok AE; Tjan-Heijnen VCG; Bos MEMM;
    Acta Oncol; 2022 May; 61(5):619-624. PubMed ID: 35139727
    [No Abstract]   [Full Text] [Related]  

  • 17. Neoadjuvant Chemotherapy in Synchronous Bilateral Breast Cancer With Different HER2 Types.
    Ma T; Mao Y; Wang HB
    Am J Ther; 2021 Nov-Dec 01; 28(6):e769-e772. PubMed ID: 34757968
    [No Abstract]   [Full Text] [Related]  

  • 18. Rate of pathological complete response in early HER2 breast cancer.
    Bodet ML; Rouzier R; Héquet D
    Bull Cancer; 2022 Jun; 109(6):722-723. PubMed ID: 35562230
    [No Abstract]   [Full Text] [Related]  

  • 19. HER2 positivity is not associated with adverse prognosis in high-risk estrogen receptor-positive early breast cancer patients treated with chemotherapy and trastuzumab.
    Li S; Wu J; Huang O; He J; Zhu L; Chen W; Li Y; Chen X; Shen K
    Breast; 2020 Dec; 54():235-241. PubMed ID: 33166784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New European Medicines Agency approval: Tucatinib in association with trastuzumab and capecitabine for the treatment of HER2-positive metastatic breast cancer previously treated].
    Bonnemort J; Bellesoeur A
    Bull Cancer; 2021; 108(7-8):673-675. PubMed ID: 34172272
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.